Sharekhan's research report on Strides Pharma Science
Q3FY2021 was a weak quarter for Strides on the back of weak flu season, & price erosion in US markets and one off expenses. The results missed estimates. Healthy growth in the base business and strong product launch pipeline provides ample visibility for growth of the US business. Growth prospects in other regulated markets are also likely to get better, led by new product launches, increased market share, and portfolio optimization efforts. Strong growth prospects and earnings visibility, improving balance sheet strength, and healthy return ratios would support multiple re-ratings.
Outlook
We retain Buy recommendation on Strides Pharma Sciences (Strides) with a revised PT of Rs 1,020.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
